Nanomedicines: From Bench to Bedside and Beyond

Aaps Journal(2016)

引用 111|浏览34
暂无评分
摘要
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients.
更多
查看译文
关键词
academic-industrial collaboration,ADME,biodistribution,CMC,oncology,PK/PD,preclinical,quality by design,targeted delivery,toxicology
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要